News publication
Everything we hold that bionity.com published.
Every article we hold from bionity.com.
Australian chronic-pain drug developer Spinifex Pharmaceuticals has agreed to be bought by Novartis for US$200 million upfront plus milestone payments; the piece recalls its 2005, 2008 and 2014 venture rounds.
Under GBS Ventures ·leads this story in the feed
Fibrotech Therapeutics raised $3 million in Series A backing from Brandon Capital-managed funds MRCF, BBF1 IIF and Uniseed to advance fibrosis drug FT011 through Phase Ib trials.
Deals recorded from bionity.com's coverage. A round is listed once, however many of their articles mention it.
| Company | Stage | Announced | Amount | Investors |
|---|---|---|---|---|
| Spinifex Pharmaceuticals | Series C | 13 May 2014 | US$45m (A$48.3m) | |
| Spinifex Pharmaceuticals | Unnamed stage | Jul 2005 | $3.2m |
Companies named in bionity.com's articles, most-covered first.
| Company | What it does | Articles |
|---|---|---|
| Brandon Capital Partners | 1 | |
| Fibrotech Therapeutics | 1 | |
| GBS Venture Partners Ltd. | 1 | |
| Novartis International | 1 | |
| Spinifex Pharmaceuticals | UQ spin-out sold to Novartis in 2015 | 1 |
| St Vincent's Hospital Melbourne | Hospital where preliminary human testing of Fluent's interface took place | 1 |
| The University of Queensland | 1 | |
| University of Melbourne | University operating the Melbourne Connect innovation precinct | 1 |
Investors named in bionity.com's articles, most-covered first.
| Investor | What it does | Articles |
|---|---|---|
| Uniseed | Venture fund backing early-stage deep tech and life science companies | 2 |
| Brandon Capital | 1 | |
| Canaan Partners | 1 | |
| Medical Research Commercialisation Fund | Venture fund commercialising biomedical research into medical products | 1 |
| Novo Ventures | 1 | |
| UniQuest | UQ’s commercialisation company | 1 |